Catalyst Biosciences to Present at 19th Annual BIO CEO & Investor Conference
February 03 2017 - 8:00AM
Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced that Nassim Usman,
Ph.D., President and Chief Executive Officer, will present a
corporate overview at the 19th Annual BIO CEO & Investor
Conference, being held in New York City February 13-14, 2017.
BIO
CEO & Investor Conference – Catalyst Biosciences Presentation
Details |
Date: |
Monday, February 13,
2017 |
Time: |
4:30 p.m. Eastern
Time |
Location: |
Waldorf Astoria, Louis
XVI Room |
To schedule a meeting with the Catalyst Biosciences management
team at this conference, please contact LifeSci Advisors.
About Catalyst Catalyst is a
clinical-stage biopharmaceutical company focused on developing
novel medicines to address hematology indications. Catalyst is
focused on the field of hemostasis, including the subcutaneous
prophylaxis of hemophilia and facilitating surgery in individuals
with hemophilia. Catalyst’s most advanced program is an improved
next-generation coagulation Factor VIIa variant, marzeptacog alfa
(activated), that has successfully completed an intravenous Phase 1
clinical trial in individuals with severe hemophilia A or B.
Catalyst is also developing a next-generation Factor IX variant, CB
2679d/ISU304, that is in advanced preclinical development. For more
information, please visit www.catbio.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statement of
historical facts, included in this press release regarding our
strategy, future operations, and plans are forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Catalyst’s clinical trial
timelines and the potential uses and benefits of subcutaneously
dosed marzeptacog alfa (activated) and CB 2679d/ISU304. Actual
results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially from the
forward-looking statements that Catalyst makes, including, but not
limited to, the risk that trials and studies may be delayed and may
not have satisfactory outcomes, that human trials will not
replicate the results from animal studies, that potential adverse
effects may arise from the testing or use of Catalyst’s products,
including the generation of antibodies, the risk that costs
required to develop or manufacture Catalyst’s products will be
higher than anticipated, competition and other factors that affect
our ability to successfully develop, manufacture and commercialize
our product candidates described in the “Risk Factors” section of
the Company’s Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q filed with the SEC. Catalyst does not assume any
obligation to update any forward-looking statements, except as
required by law.
Contacts:
Investors:
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
650.871.0761
investors@catbio.com
Media:
Denise Powell
Red House Consulting, LLC
510.703.9491
denise@redhousecomms.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024